Sodium cromoglicate 1mg/dose / Salbutamol 100micrograms/dose inhaler with spacer

BACKGROUND: The pain of renal colic, mediated in part by ureteral spasm and inflammation, is often severe and difficult to control. Salbutamol has been shown to cause ureteral relaxation, but its effects on the pain of renal colic have never been studied. The objective of this trial was to investigate whether the use of intravenous salbutamol in addition to standard analgesia was associated with greater pain reduction compared with standard analgesia alone in patients presenting to emergency departments (EDs) with renal colic. METHODS: This single-centre, double-blind, phase II, randomised, placebo-controlled trial recruited adult (≥18 years) ED patients with clinically suspected renal colic. Participants were randomised in a 1:1 ratio to receive either 250 µg of intravenous salbutamol or a placebo (0.9% sodium chloride). The primary outcome was the difference in the change in pain scores (measured on a 100 mm Visual Analogue Scale) from baseline to 30 min following trial treatment administration in participants with subsequently confirmed renal colic. A modified intention-to-treat analysis was undertaken for the primary population of participants with confirmed renal colic. RESULTS: Consent was obtained from 151 patients; 108 participants with confirmed renal colic were included in the primary outcome analysis. There was no statistical difference between groups in median change in pain score at 30 min (salbutamol group -18 mm (IQR -25 to -3), placebo group -13 mm (IQR -33 to -1), difference 5 mm (95% CI -16 to 6, p=0.575)). No significant differences were found in the secondary outcomes related to pain, patient satisfaction or opiate requirement.More adverse events (AEs) were observed in the salbutamol group (65) compared with placebo (42, p=0.02); no unexpected AEs were identified. CONCLUSIONS: This trial has not identified a clinically or statistically significant benefit from the addition of intravenous salbutamol to standard care for patients presenting to an ED with pain caused by renal colic. TRIAL REGISTRATION NUMBERS: The trial was registered with the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT), reference 2018-004305-11. It was also registered with the ISRCTN Registry, reference 14552440.

Abstract licence: CC BY

Abstract Analytical chemistry research has shifted towards environmentally friendly substitutes that reduce waste and avoid hazardous substances. These efforts align with broader environmental goals and inspire sustainable and responsible science. The objective of this work is to develop and validate an analytical method and verify its greenness using specific tools, including analytical GREEnness (AGREE), analytical greenness metric for sample preparation (AGREEprep), green analytical procedure index, complex green analytical procedure index, analytical Eco-Scale, analytical method volume intensity, analytical method greenness score, and HPLC-EAT (Environmental Assessment Tool). Effective treatment of chronic cough relies heavily on adequately utilizing salbutamol (SAL) and guaifenesin (GUA) in the presence of sodium benzoate (SOB) preservative. The isocratic elution mode used the Zorbax Eclipse Plus C18 column (15 cm × 4.6 mm, 3.5 µm). It could move 1.5 mL·min −1 , hold 50 µL, have a column temperature of 30°C, and have an autosampler temperature of 5°C. It could detect UV light at 276 nm and had a mobile phase of 80:20 v/v buffer solution and acetonitrile. We have successfully established highly accurate calibration curves for the three components SAL, GUA, and SOB within the optimal range of 2–50 µg·mL −1 . The coefficient of correlation ( r ) for these curves was at an impressive 0.9999 for SAL and GUA, while it was 0.9998 for SOB. The recovery values were 100.15%, 100.47%, and 100.92% for SAL, GUA, and SOB, respectively. The selectivity and sensitivity to the ingredients were confirmed according to the International Council for Harmonisation guidelines, as no interference occurred from any of the used sample components. We implemented Six Sigma, resulting in precision and productivity.

Abstract licence: CC BY

Background: While tools exist for objective cough counting in clinical studies, there is no available tool for objective cough measurement in clinical practice. An artificial intelligence (AI)-based cough count system was recently developed that quantifies cough sounds collected through a smartphone application. In this prospective study, this AI-based cough algorithm was applied among real-world patients with an acute exacerbation of asthma. Methods: Patients with an acute asthma exacerbation recorded their cough sounds for 7 days (2 consecutive hours during awake time and 5 consecutive hours during sleep) using CoughyTM smartphone application. During the study period, subjects received systemic corticosteroids and bronchodilator to control asthma. Coughs collected by application were counted by both the AI algorithm and two human experts. Subjects also provided self-measured peak expiratory flow rate (PEFR) and completed other outcome assessments [e.g., cough symptom visual analogue scale (CS-VAS), awake frequency, salbutamol use] to investigate the correlation between cough and other parameters. Results: A total of 1,417.6 h of cough recordings were obtained from 24 asthmatics (median age =39 years). Cough counts by AI were strongly correlated with manual cough counts during sleep time (rho =0.908, P<0.001) and awake time (rho =0.847, P<0.001). Sleep time cough counts were moderately to strongly correlated with CS-VAS (rho =0.339, P<0.001), the frequency of waking up (rho =0.462, P<0.001), and salbutamol use at night (rho =0.243, P<0.001). Weak-to-moderate correlations were found between awake time cough counts and CS-VAS (rho =0.313, P<0.001), the degree of activity limitation (rho =0.169, P=0.005), and salbutamol use at awake time (rho =0.276, P<0.001). Neither awake time nor sleep time cough counts were significantly correlated with PEFR. Conclusions: The strong correlation between cough counts using the AI-based algorithm and human experts, and other indicators of patient health status provides evidence of the validity of this AI algorithm for use in asthma patients experiencing an acute exacerbation. Study findings suggest that CoughyTM could be a novel solution for objectively monitoring cough in a clinical setting.

Abstract licence: CC BY-NC-ND

Abstract Bromhexine (BR), guaiafenesin (GUF) and salbutamol (SAL) are formulated as Ventocough syrup® (with and without sugar), labeled to contain propyl paraben and sodium benzoate as inactive ingredients. They are used to make coughing more productive and easier. A crucial element and a major issue in the pharmaceutical industry is the control of organic related impurities to obtain safe and effective treatment. Guaiacol (GUL) is reported to be GUF related impurity that was proved to be extremely toxic (toxic rating class 5), and its use should be banned. In this work, In-Silico study and ADMET estimation were conducted to predict GUL pharmacokinetic properties and its toxicity profile. Additionally, two chromatographic methods were conducted to analyze the studied components along with GUF impurity in the presence of the labeled dosage form excipients. The In-Silico study assured that GUL has oral rat acute toxicity and it is considered to be skin sensitizer. On the other hand, the developed TLC- densitometeric method depended on using a mobile phase mixture of hexane: methylene chloride: triethylamine (5.0:6.0:0.3, by volume) as a developing system. UV-Scanning was performed immediately at 275 nm for SAL, GUF and GUL, while scanning at 310 nm was used for scanning BR. Linearity was established in the ranges of 0.25–4.0, 0.25–4.0, 0.5–8.0 and 0.1–1.6 µg/band for BR, SAL, GUF and GUL, respectively. In the developed HPLC method, separation was performed on X-Bridge® C 18 column (250 × 4.6 mm, 5 μm) using a solvent mixture of 0.05M disodium hydrogen phosphate pH 3 with aqueous phosphoric acid: methanol (containing 0.3%, v/v triethylamine) (40:60, v/v). Detection was done at 225 nm and separation was achieved within 10 min. Linearity was proved in the range of 2–50 µg/mL for the proposed drugs. Validation of the developed methods was done and all the calculated parameters were within the acceptable limits recommended by ICH guidelines. After that, methods were used to examine the potency of the selected marketed dosage forms and concentrations of all drugs were within the acceptable limits. Additionally, complete separation between the studied drugs and the additives were observed. The developed methods can be used during routine quality control analysis of the proposed drugs when the required issues concern on sensitivity, selectivity and analysis time. Graphical Abstract

Abstract licence: CC BY

Hyperkalemia is a common electrolyte abnormality frequently complicated with chronic kidney disease. By injecting potassium chloride (KCl) solutions intravenously into bullfrogs, we reproduced typical electrocardiogram (ECG) abnormalities of hyperkalemia in the frog hearts, such as the peaked T waves and the widening of QRS complexes. Simultaneous recordings of cardiac action potentials showed morphological changes that synchronized with those of ECG. After 100 mM KCl injection, the widened QRS complexes continued for a while and gradually restored to their baseline widths. However, pre-treatment with sodium bicarbonate or salbutamol, which directly or indirectly stimulates Na+/K+-ATPase activity, significantly facilitated the recovery from the widened QRS duration, indicating the transcellular movement of potassium ions from the extracellular fluid into the intracellular stores.

Abstract licence: CC BY-NC-ND

ABSTRACT Difficulty in swallowing drug and slow onset of action of drug are common problems of conventional tablet. Orally disintegrating tablet (ODT) is an innovative dosage form to overcome the problem of swallowing drug and provide quick onset of action of drug because it can disintegrates quickly when contact with saliva in less than 3 minutes. This study formulate and evaluate ODT containing salbutamol sulphate to relieve the respiratory disorders immediately. Materials that affect the disintegration time of ODT are superdisintegrants and binders. Sodium Starch Glycolate (SSG) is a superdisintegrant that has high swelling capacity and its efficiency is not affected by compression and hydrophobic materials. PVP K-30 is a water soluble binder that effective to increase hardness and decrease friability of ODT without prolonging the disintegration time. The aim of this study is to optimize SSG and PVP K-30 to get the optimum formula of ODT salbutamol sulphate. ODT salbutamol sulphate was made by direct compression method. The optimization was carried out using two-level and two-factor of factorial design. Disintegration time, hardness, and friability of ODT were responses that evaluated to get the optimum formula of ODT salbutamol sulphate. The result showed that SSG affected in increasing of disintegration time of ODT. PVP K-30 affected in increasing of disintegration time, decreasing friability, and increasing hardness of ODT. The optimum formula contained 4% of SSG and 1,5% of PVP K-30 resulted in 37,58 seconds of disintegration time, 4,713 kg/cm2 of hardness, and 0,6298% of friability. The optimum formula dissolved 92.296 % after 30 minute. Keywords : Orally disintegrating tablet; salbutamol sulphate; SSG; PVP K-30

Abstract licence: CC BY-SA

Salbutamol one of asthma medicine which can be made in to dispersible tablet with the addition of sodium saccharin as sweetener. This study aimed to determine effect of increasing concentration of sodium saccharin as sweetener on physical properties and patient acceptabelity of the tablet. The tablet was made into 5 formulas with the 0% of sodium saccharin concentration as Formula 1, 0.2% as Formula 2, 0.4% as Formula 3, 0.6% as Formula 4, and 0.8% as Formula 5. The tablet made by direct compression method. The evaluation of granule including flow time test, angle of repose, and compressibility test. The tablet evaluation including organoleptic, weight uniformity, size uniformity, friability, hardness, wetting time, disintegration time, content uniformity, and hedonic test. The results of the physial properties were the hardness F1 until F5 subsequently 1.70, 1.54, 2.48, 2.67, and 2.73 Kp; the disintegration time F1 until F5 subsquently 55.67, 56.67, 56.67, 57.00, and 58.00 seconds; the friability test 1.09, 1.98, 0.77, 0.65, and 0.63%. The results showed that there were significant differences among all the formulas. It could be concluded that increasing concentration of sodium saccharin as sweetener in salbutamol dispersible tablet increase physical properties and could be made as preferable and acceptable tablet.

Abstract licence: CC BY